Pfizer is a well-respected drugmaker facing typical industry headwinds. The company is financially strong, and new drug development is slowly gaining traction.
Retirees hunting for income often reach for low-priced shares, but a share price only sets the cost of a single share. Valuation multiples, payout coverage and balance sheet strength decide whether a dividend stock is cheap or a trap.
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
When a stock falls out of favor, the balance sheet decides what happens to your income. A company with manageable debt and steady cash flow can keep paying shareholders while it repairs the business.
A risk-free Treasury bill sounds hard to beat, yet three dividend payers in healthcare, tobacco, and pipelines offer more income. Each one also hides a risk that could turn a fat yield into a costly lesson.
One of these high yields keeps paying monthly while its book value shrinks, and another looks safe until you check the debt. Before trusting a big payout in retirement, see which four stocks fail the coverage test and which one passes.
JEPI's monthly check looks generous until you notice what it quietly cost retirees in a single year. Four dividend payers trade a smaller paycheck today for raises, tax perks, and rallies you actually keep, but each carries a risk worth knowing.